InvestorsHub Logo
icon url

02opida

04/07/24 7:57 AM

#616457 RE: 02opida #616456

NVS - New Novartis data show early addition of twice-yearly* Leqvio(TM) (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting